Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Assets (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Non-Current Assets for 11 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 13.62% year-over-year to $3.5 million, compared with a TTM value of $3.5 million through Sep 2025, down 13.62%, and an annual FY2024 reading of $4.6 million, up 86.98% over the prior year.
  • Non-Current Assets was $3.5 million for Q3 2025 at Sunshine Biopharma, down from $4.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.7 million in Q1 2025 and bottomed at $1642.0 in Q2 2022.
  • Average Non-Current Assets over 5 years is $2.0 million, with a median of $2.2 million recorded in 2023.
  • The sharpest move saw Non-Current Assets plummeted 87.82% in 2022, then surged 140662.06% in 2023.
  • Year by year, Non-Current Assets stood at $7061.0 in 2021, then surged by 27254.68% to $1.9 million in 2022, then grew by 27.2% to $2.5 million in 2023, then soared by 86.98% to $4.6 million in 2024, then decreased by 23.38% to $3.5 million in 2025.
  • Business Quant data shows Non-Current Assets for SBFM at $3.5 million in Q3 2025, $4.1 million in Q2 2025, and $4.7 million in Q1 2025.